Feaeral Register / Vol. 56. No. 48 / Tuesday. March 12. 1991 / Notices 
10441 
Rockville Pike, Bethesda, Maryland 
20892. tel. (301) 496-5708. will provide 
summaries of the meeting and rosters of 
committee members, upon request. 
Dr. Cedric W. Long, Executive 
Secretary, Frederick Cancer Research 
and Development Center Advisory 
Committee, National Cancer Institute 
Frederick Cancer Research and 
Development Center, P.O. Box B, 
Frederick, Maryland 21702-1201, tel. 
(301) 846-1108, will provide substantive 
program information upon request. 
(Catalog of Federal Domestic Assistance 
Program Numbers: 93.393, Cancer Cause and 
Prevention Research: 93.394, Cancer 
Detection and Diagnosis Research; 93.395, 
Cancer Treatment Research; 93.396, Cancer 
Biology Research: 93.397, Cancer Centers 
Support 93.398, Cancer Research Manpower; 
93.399, Cancer Control.) 
Dated; March 4. 1991. 
Betty J. Beveridge, 
Committee Management Officer, NIH. 
[FR Doc. 91-5713 Fded 3-11-91; 8:45 am] 
BILUNO CODE 4140-01-M 
National Heart, Lung, and Blood 
Institute; Heart Lung and Blood 
Research Review Committee A; 
Meeting 
Pursuant to Public Law 92-463 notice 
is hereby given of the meeting of the 
Heart, Lung, and Blood Research 
Review Committee A, National Heart, 
Lung, and Blood Institute, National 
Institutes of Health, on March 28-29, 
1991 in Building 31, Conference Room 9, 
9000 Rockville Pike, Bethesda, Maryland 
20892. 
This meeting will be open to the 
public on March 28, 1991 from 8 a.m. to 
approximately 9 a.m. to discuss 
administrative details and to hear 
reports concerning the current status of 
the National Heart Lung, and Blood 
Institute. Attendance by the public will 
be limited to space available. 
In accordance with the provisions set 
forth in sections 522b(c)(4) and 
552b(c)(6), title 5, U.S.C. and section 
10(d) of Public Law 92-463, the meeting 
will be closed to the public on March 28 
from approximately 9 a.m. imtil recess 
and from 9 a.m. until adjournment on 
March 29, for the review, discussion and 
evaluation of individual grant 
applications. These applications and the 
discussions could reveal confidential 
trade secrets or commercial property 
such as patentable material, and 
personal information concerning 
individuals associated with the 
applications, the disclosure of which 
would constitute a clearly unwarranted 
ii.vasion of personal privacy. 
Ms. Terry Bellicha, Chief, 
Communications and Public Information 
Branch, National Heart, Lung, and Blood 
Institute, Building 31, room 4A21, 
National Institutes of Health, Bethesda, 
Maryland 20892, (301) 496-4236 will 
provide a summary of the meeting and a 
rostpr of the committee members. 
Dr. Robert M. Chasson, Executive 
Secretary (Acting), Heart Lung, and 
Blood Research Review Committee A. 
Westwood Building, room 552, National 
Institutes of Health, Bethesda, Maryland 
20892, (301) 496-7917, will furnish 
substantive program information. 
(Catalog of Federal Domestic Assistance 
Program Nos. 13.637, Heart and Vascular 
Diseases Research; 13.638, Lung Diseases 
Research; National Institutes of Health.) 
Dated: March 4, 1991. 
Betty J. Beveridge, 
Committee Managemepf Officer, NIH. 
[FR Doc. 91-5714 Filed 03-11-91; 8:45 am] 
BiLUNQ CODE 4140-01-M 
National Heaii, Lung, and Blood 
Institute; Heart, Lung, and Blood 
Research Review Committee B; 
Meeting 
Pursuant to Public Law 92-463, notice 
is hereby given of the meeting of the 
Heart Lung, and Blood Research 
Review Committee B, National Heart 
Lung, and Blood Institute, National 
Institutes of Health, on March 28, 1991 in 
Building 31, Conference Room 9, 9000 
Rockville Pike, Bethesda, Maryland 
20892. 
This meeting will be open to the 
public on March 28 from 8 a.m; to 
approximately 9 a.m. to discuss 
administrative details and to hear 
reports concerning the current status of 
the National Heart, Lung, and Blood 
Institute. Attendance by the public will 
be limited to space available. 
In accordance with the provisions set 
forth in sections 522bfc)(4) and 
552b(c)(6), title 5, U.S.C. and section 
10(d) of ^blic Law 92-463, the meeting 
will be closed to the public on March 28 
from approximately 10 a.m. until 
adjournment for the review, discussion 
and evaluation of individual grant 
applications. These applications and the 
discussions could reveal confidential 
trade secrets or commercial property 
such as patentable material, and 
personal information concerning 
individuals associated with the 
applications, the disclosure of which 
would constitute a clearly unwarranted 
invasion of personal privacy. 
Ms. Terry Bellicha, Chief, 
Communications and Public Information 
Branch, National Heart, Lung, and Blood 
Institute, Building 31, room 4A21, 
National Institutes of Health, Bethesda, 
Maryland 20892, (301) 496-4236 will 
provide a summary of the meeting a d 
roster of the committee members. 
Dr. Jeffrey H. Hurst. Executive 
Secretary. Heart, Lung, and Blood 
Research Review Committee B, 
Westwood Building, room 5A-10,' 
National Institutes of Health, Bethesd- 
Maryland 20892, (301) 496-4485. will 
furnish substantive program 
information. 
(Catalog of Federal Domestic Assistance 
Program Nos. 13.837, Heart and Vascula*' 
Diseases Research; 13.838, Lung Diseases 
Research, National Institutes of Health.) 
Dated: March 4, 1991. 
Betty J. Beveridge, 
Committee Management Officer, NIH. 
[FR Doc. 91-5715 Filed 3-11-91; 8:45 am] 
BILUNO CODE 4140-01-M 
Human Gene Therapy Subcommittee; 
Meeting; Amendment 
Notice is hereby given of an 
amendment to the notice of meeting 
published in the Federal Register on 
March 7, 1991. The April 5, 1991, meeting 
will include discussion of an additional 
proposed action under the NIH 
Guidelines for “Research Involving 
Recombinant DNA Molecules” (51 FR 
16958): 
VI. Amendment in the “Points to 
Consider in the Design and Submission 
of Protocols for the Transfer of 
Recombinant DNA into the Genome of 
Human Subjects/Dr. Mclvor 
In a letter dated March 4, 1991, Dr. R. 
Scott Mclvor of the University of 
Minnesota requested an amendment to 
the “Points to Consider in the Design 
and Submission of Protocols for the 
Transfer of Recombinant DNA into the 
Genome of Human Subjects" as 
published in the Federal Register (41 FR 
7445) to read: 
(I.B.2) Preclinical studies, including risk 
assessment studies. Results demonstrating 
the safety, efficacy and feasibility of the 
proposed procedures using the most relevant 
animal and/or cell culture model systems 
should be included. Describe the 
experimental basis (derived from tests in 
cultured cells and animals) for claims about 
efficacy and safety of the proposed system 
for delivery and explain why the model(s) 
chosen is (are) the most appropriate. 
FOR FURTHER INFORMATION: Contact Dr. 
Nelson A. Wivel, Director, Office of 
Recombinant DNA Activities. National 
Institutes of Health. Building 31. room 
4B11, Bethesda, Maryland 20892, 
telephone (301) 496-9838, fax (301) 496- 
9839. 
[554] 
Recombinant DNA Research, Volume 14 
